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Human Fecal Metabolism of Soyasaponin I
JIANG HU,† YAN L. ZHENG,† WALTER HYDE,‡ SUZANNE HENDRICH,† AND
PATRICIA A. MURPHY*,†
Department of Food Science and Human Nutrition, and College of Veterinary Medicine,
Iowa State University, 2312 Food Science Building, Ames, Iowa 50011
The metabolism of soyasaponin I (3-O-[R-L-rhamnopyranosyl-â-D-galactopyranosyl-â-D-glucuronopy-
ranosyl]olean-12-ene-3â,22â,24-triol) by human fecal microorganisms was investigated. Fresh feces
were collected from 15 healthy women and incubated anaerobically with 10 mmol soyasaponin I/g
feces at 37 °C for 48 h. The disappearance of soyasaponin I in this in vitro fermentation system
displayed apparent first-order rate loss kinetics. Two distinct soyasaponin I degradation phenotypes
were observed among the subjects: rapid soyasaponin degraders with a rate constant k ) 0.24 (
0.04 h-1 and slow degraders with a k ) 0.07 ( 0.02 h-1. There were no significant differences in the
body mass index, fecal moisture, gut transit time, and soy consumption frequency between the two
soyasaponin degradation phenotypes. Two primary gut microbial metabolites of soyasaponin I were
identified as soyasaponin III (3-O-[â-D-galactopyranosyl-â-D-glucuronopyranosyl]olean-12-ene-3â,-
22â,24-triol) and soyasapogenol B (olean-12-ene-3â,22â,24-triol) by NMR and electrospray ionized
mass spectroscopy. Soyasaponin III appeared within the first 24 h and disappeared by 48 h.
Soyasapogenol B seemed to be the final metabolic product during the 48 h anaerobic incubation.
These results indicate that dietary soyasaponins can be metabolized by human gut microorganisms.
The sugar moieties of soyasaponins seem to be hydrolyzed sequentially to yield smaller and more
hydrophobic metabolites.
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INTRODUCTION
Saponins are a family of steroid or triterpenoid glycosides
found in a wide variety of plants. Soyasaponins are triterpenoid
glycosides with one or two polysaccharide chains mainly present
in legumes (1). Significant amounts of soyasaponins are found
in soybeans and soy products between 0.5 and 114 ímol/g (2).
The potential relationship of soyasaponins to health effects has
been suggested. Soyasaponins seem to be significant contributors
to the cholesterol lowering effect of soy consumption (3, 4).
Soyasaponins showed anticarcinogenic activity against various
tumors or tumor cell lines (5-8) and have been shown to have
hepatoprotective and antiviral activities (9-11).
It is important to understand the intestinal metabolism and
absorption of soyasaponins because humans obtain soyasaponins
from the diet. The forms of soyasaponins that are most likely
to be involved in the potential health effects of these compounds
are not known. Most studies investigating the biological effects
of soyasaponin have been limited to in vitro experiments and a
few animal studies. Data on the bioavailability and absorption
of saponins are scarce. Gestetner et al. (12) reported that ingested
soyasaponins were hydrolyzed to aglycones by nonspecific
glycosidases of cecal microflora in chicks, rats, and mice.
Karikura et al. (13) observed that ginseng saponins were
hydrolyzed into smaller molecules with removal of the sugar
moieties in the rat intestine. However, no study has reported
the fate of soyasaponins or explored their possible metabolites
in humans.
The present study was designed to investigate whether
soyasaponins were metabolized by human gut microorganisms
using a model fecal incubation system and to identify gut
metabolites of soyasaponins. Soyasaponin I (Figure 1), as a
representative soyasaponin, was examined in this study because
it is the predominant form of soyasaponin in heat-treated soy
products (2). Individual variability in soyasaponin metabolism
by human gut microflora was evaluated, and soyasaponin
catabolic phenotype among human subjects was characterized.
Gut microorganism populations and bacterial enzyme activities
have been known to be affected by factors such as genetic
background, dietary habits, and physical activity in humans (14).
Therefore, the influence of individual status, such as body
composition, ethnicity, gut transit time (GGT), and soy con-
sumption on fecal metabolism of soyasaponins, was examined
as well. The information obtained in this study will help to
predict soyasaponin bioavailability in humans and provide
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evidence of the presence of soyasaponin metabolites in the
human intestine.
MATERIALS & METHODS
Preparation of Soyasaponin I and III and Soyasapogenol B
Standards. Soyasaponin I was isolated using the method of Hu et al.
(2) from soy germ donated by Acatris (Minneapolis, MN). Soyasaponin
III was produced by hydrolyzing 100 mg of soyasaponin I in 1 N
hydrochloric acid-dioxane (1:1, v/v) by refluxing for 1 h. The reaction
mixture was neutralized by 10 N sodium hydroxide and desalted with
a high capacity C18 SPE column (Alltech Associates Inc., Deerfield,
IL) eluting sequentially with 150 mL of water and 100 mL of methanol.
Crude soyasaponin III was obtained in the methanol fraction. A yield
of 43 mg of soyasaponin III was obtained by further purification with
a semipreparative high-performance liquid chromatography (HPLC)
system as previously described (2). Soyasapogenol B was produced
by hydrolyzing 100 mg of crude group B soyasaponins (generously
provided by Dr. Mark Berhow, National Center for Agricultural
Utilization Research, USDA, Peoria, IL) in 3 N hydrochloric acid by
refluxing for 3 h. The reaction mixture was neutralized, desalted as
described above, and then purified with the semipreparative HPLC
system using 70% aqueous acetonitrile with 1 mM ammonium acetate
at a 2 mL/min flow rate. A yield of 24 mg of purified soyasapogenol
B was obtained as a white amorphous powder.
The structural identity of the purified soyasaponin standards was
confirmed by electrospray ionized (ESI) mass spectroscopy and 1H and
13C NMR analyses. ESI spectra were acquired in the positive Q1MS
mode on a Finnigan TSQ 700 triple quadrupole mass spectrometer
(Finnigan MAT, San Jose, CA) fitted with a Finnigan ESI interface.
1H NMR and 13C attached proton test NMR spectra were acquired on
a Varian VXR-300 spectrometer (Varian Inc., Palo Alto, CA). The
samples were dissolved in chloroform-d6 or dimethyl sulfoxide-d6
(Cambridge Isotope Laboratories, Inc., Andover, MA) with tetrameth-
ylsilane (Cambridge Isotope Laboratories, Inc.) as an internal standard.
The spectra obtained for these purified compounds were in good
agreement with those reported by Baxter (15) and Kudou et al. (16).
Anaerobic Incubation of Soyasaponin I with Human Fecal
Microflora. The subjects were 15 healthy women recruited from Iowa
State University and the surrounding community. They were 18-52
years of age, with a body mass index (BMI) of 23.0 ( 5.8 kg/m2, and
had not used any medication for 3 months prior to and during the study.
The subjects included ten Caucasians, four Chinese, and one Asian
Indian. The study protocol was reviewed and approved by Iowa State
University Human Subjects in Research Committee in 2001.
Brain-heart infusion media (BHI) was prepared according to Zheng
(17). Soyasaponin I was added to BHI media in a concentration of 1.6
ímol/mL. All media were saturated with CO2 and autoclaved.
The subjects were instructed to avoid soyasaponin-containing foods
for 4 days prior to fecal collection as a washout period. One fresh stool
from each subject was collected into a sterile plastic bag at the end of
the washout period. Feces were manually homogenized in the sealed
bag. Ten grams of feces was added to 25.0 mL of sterilized BHI media
and mixed by vortexing. The fecal suspension (10 mL) was inoculated
into 25.0 mL of BHI media containing soyasaponin I to give an initial
concentration of 10 ímol soyasaponin I/g feces. The mixture was
incubated anaerobically at 37 °C for 48 h. Parallel incubation was
performed without soyasaponin I present in the media for each subject
as a negative control. Two types of positive controls were included as
follows: BHI media containing soyasaponin I without feces and BHI
media containing soyasaponin I cultured with autoclaved fecal suspen-
sion. Culture aliquots were taken at 0, 4, 8, 12, 24, 36, and 48 h and
immediately frozen at -20 °C until analysis.
The samples were thawed to room temperature (RT) before soyasa-
ponin analysis. A 2.0 mL aliquot of each sample was dispersed in 8
mL of methanol in a 15 mL polypropylene centrifuge tube and shaken
at RT for 30 min. The suspension was centrifuged at 15 000g for 10
min. The supernatant was removed, and the precipitate was resuspended
in 10 mL of methanol. After the mixture was vortexed for 15 min, the
sample suspension was centrifuged again. After the second centrifuga-
tion, the two supernatants were combined and evaporated to dryness
under reduced pressure at RT. The residue was resuspended in 5 mL
of 20% methanol and loaded onto a preconditioned Sep-Pak cartridge
(classic short-body C18, Waters Corp., Milford, MA). The cartridge was
washed with 5 mL of 5% methanol. Soyasaponin was eluted with 2.0
mL of HPLC grade methanol. The extract was vortexed and subjected
to thin-layer chromatography (TLC) and HPLC. Samples were extracted
and analyzed in duplicate. The logarithm of the remaining soyasaponin
I concentration was plotted vs incubation time. The soyasaponin I
disappearance reaction rate loss constant k and half-life t1/2 were
calculated according to Labuza and Riboh (18).
TLC analyses were performed on the LK6F silica gel plates
(Whatman, Hillsboro, OR). Each set of fecal incubation samples per
subject was analyzed using two different solvent conditions: one was
developed with n-butanol-ethanol-aqueous ammonia (5:5:4, v/v), and
the other was developed with hexanes-ethyl acetate (2:1, v/v).
Soyasaponins were detected after spraying acetic acid-sulfuric acid-
anisaldehyde (100:2:1, v/v) and heating at 120 °C for 10 min.
Soyasaponin I concentration and metabolite formation were deter-
mined by HPLC using the method previously reported (2). The mobile
phases were 0.05% trifluoroacetic acid in water (solvent A) and 0.05%
trifluoroacetic acid in acetonitrile (solvent B). The gradient elution was
carried out as: solvent B held at 37% for 3 min, increased from 37 to
40% in 12 min, then solvent B increased to 48% in 25 min, and finally
solvent B increased to 100% in 1 min and held at 100% for 2 min.
The gradient program recycled back to the initial state of 37% solvent
B in 5 min. The column temperature was 30 °C. The injection volume
was 50 íL. The flow rate was 1 mL/min, and the UV absorbance was
monitored from 190 to 350 nm.
To monitor the formation of more hydrophobic metabolites in the
culture, the samples were analyzed with the same HPLC system using
a different gradient program: solvent B increased linearly from 73 to
100% in 35 min and then solvent B recycled back to 73% in 4 min.
Identification of Soyasaponin I Metabolites. The metabolites of
soyasaponin I formed in the culture were isolated as described below.
Five grams of fresh human feces was anaerobically incubated in 50
mL of BHI media containing 50 mg of soyasaponin I at 37 °C for 48
h. Two 25 mL aliquots were taken at 12 and 48 h separately. Each
sample was fractionated with a high capacity C18 SPE column (Alltech
Associates Inc.) by successively eluting with 150 mL of water, 150
mL of 30% aqueous methanol, and 100 mL of methanol. The eluted
fractions containing metabolites were further separated on preparative
TLC (PK6F, Whatman) to give 12 mg of metabolite I and 20 mg of
metabolite II. The metabolites were analyzed by analytical HPLC and
TLC. Their Rf values on TLC and retention times on HPLC were
compared with authentic standards.
Fecal incubation samples at each time point from the selected subjects
were analyzed by LC-atmospheric pressure chemical ionization (ApCI)-
MS to further confirm the chemical identity of the metabolites. The
Figure 1. Structures of soyasaponin I and its metabolites.
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analyses were conducted on a Hewlett-Packard HPLC system (Agilent
Technologies, Wilmington, DE) coupled with a triple quadrupole LC-
MS-MS mass spectrometer (VG Biotech, Manchester, U.K.). Sample
separation was carried out under the same HPLC gradient programs as
described above except that the flow rate was 0.525 mL/min. The
injection volume ranged from 5 to 20 íL depending on the concentration
of the analytes in the solution. The effluent was delivered to the
electrospray source configured with a corona discharge pin. Nitrogen
gas was used as the nebulizing and auxiliary gas for the mass
spectrometer. The parameters applied to MS were as follows: corona
discharge voltage, 3 kV; cone voltage, 30 V; ApCI probe temperature,
350 °C; source temperature, 120 °C; scan time, 2 s; and interscan time,
0.1 s. The full scan mass spectra over m/z range of 200-1100 amu
were acquired on the eluted analytes. Before analysis, the mass
spectrometer was tuned and calibrated for the range of m/z 200-1100.
The soyasaponin standards were dissolved in methanol and analyzed
to obtain authentic mass spectra prior to sample analysis.
Statistical Analysis. All results were reported as the mean (
standard deviation (SD) or mean ( mean square of error (MSE).
Statistical analyses were performed with an SAS system (Version 8.1,
SAS Institute Inc., Cary, NC). The kinetics of soyasaponin I metabolism
were analyzed by general linear regression. The phenotypic pattern in
human subjects was identified by average linkage cluster analysis (19).
A general linear model was used to analyze the differences in BMI,
stool moisture, GGT, and soy consumption frequency between soyasa-
ponin degradation phenotypes. Statistical significance was set at R )
0.05 for all analyses.
RESULTS AND DISCUSSION
The LC-MS chromatograms of standard soyasaponin I (3-
O-[R-L-rhamnopyranosyl-â-D-galactopyranosyl-â-D-glucuronopy-
ranosyl]olean-12-ene-3â,22â,24-triol), soyasaponin III (3-O-[â-
D-galactopyranosyl-â-D-glucuronopyranosyl]olean-12-ene-3â,
22â,24-triol), and soyasapogenol B (olean-12-ene-3â,22â,24-
triol) are shown in Figure 2. The ESI spectra of individual
compounds gave a primary ion peak at m/z 944 [M + H]+ for
soyasaponin I, m/z 819 [M + Na]+ for soyasaponin III, and
m/z 459 [M + H]+ for soyasapogenol B. Their ESI mass spectra
and NMR data were in good agreement with the literature (15,
16). The mass spectra of these standards by LC-ApCI-MS are
shown in Figure 3. Their retention times, Rf values, and ApCI-
MS fragmentation patterns are summarized in Table 1.
The metabolism of soyasaponin I by intestinal microflora was
examined using an in vitro static fecal fermentation model. The
TLC profile for soyasaponin I incubation showed that soyasa-
ponin I gradually disappeared and two major metabolites with
higher Rf values appeared in the culture over 48 h (Figure 4).
This indicates that soyasaponin I was converted to more
hydrophobic metabolites I and II. Metabolite II appeared to be
the primary product in the culture after 24 h of incubation.
Disappearance of soyasaponin I was not observed in the cultures
inoculated with autoclaved fecal material or without fecal
material indicating that degradation of soyasaponin I was caused
by viable fecal microorganisms and was probably enzymatic
in nature (Figure 4).
The HPLC chromatograms of cultured fecal samples at 12
and 48 h are shown in Figure 2C,E, respectively. Metabolite I
was detected along with soyasaponin I using the gradient
program of Hu et al. (2). The retention time of soyasaponin I
was 25.9 min on HPLC and an Rf value of 0.60 on TLC when
using the 1-butanol-ethanol-ammonia solvent system. Me-
tabolite I had a retention time of 29.9 min on HPLC and a Rf
value of 0.63 on TLC. The scanned mass spectrum showed
peaks at m/z 797.3 [M + H]+, 599.4 [M-rhm-gal-2H2O + H]+,
441.3 [aglycone - OH]+, 423.3 [aglycone - OH - H2O]+,
and 405.3 [aglycone - OH - 2H2O]+. Metabolite II had a
retention time of 27.4 min on HPLC under the more hydro-
phobic HPLC gradient program and a Rf value of 0.43 on TLC
using the hexanes-ethyl acetate solvent system. The scanned
ApCI mass spectrum of metabolite II showed peaks at m/z 441.3
[aglycone - OH]+, 423.3 [aglycone - OH - H2O]+, and 405
[aglycone - OH - 2H2O]+. The HPLC, TLC, and MS spectral
data of metabolites I and II matched those of soyasaponin III
and soyasapogenol B, respectively.
These results suggest that the main metabolic pathway of
soyasaponin I is the hydrolysis of terminal rhamnose from the
sugar chain of soyasaponin I to produce soyasaponin III, then
further hydrolysis of remaining sugars to yield soyasapogenol
B. However, soyasapogenol B-monoglucuronide, one of the
hypothesized metabolites of soyasaponin I, was not observed
during incubation in our study, which may be due to greater
gut microbial glucuronidase than rhamnosidase activity (20).
The hydrolysis of glucuronic acid from the aglycones may occur
so quickly that soyasapogenol B-monoglucuronide was not
detected in our hands. On the basis of these data, it is reasonable
to infer that other individual soyasaponins could be metabolized
by gut microorganisms similarly; that is, the terminal sugars
could be hydrolyzed in a stepwise manner, and the aglycones
with structural characteristics of each soyasaponin would re-
sult.
The metabolism of saponins by microorganisms has been
reported. Makkar et al. (21) demonstrated that quillaja triter-
penoid saponins disappeared when incubated with cattle rumen
liquor in vitro, suggesting the metabolism of saponins by rumen
microorganisms. Gestetner et al. (12) incubated the cecal and
colon contents of rats, chicks, and mice with soyasaponins in
vitro and detected soyasaponins and soyasapogenols in the
culture after a 3 h incubation. However, they did not report
whether any intermediate decomposition products of soyasa-
ponins were detected. Hasegawa et al. (22, 23) reported the
anaerobic metabolism of ginseng saponins by human fecal
microorganisms. They demonstrated that ginsenosides were
converted into smaller molecules by stepwise cleavage of
terminal sugars. Our results demonstrate that human intestinal
microorganisms have the ability to metabolize soyasaponins.
Gestetner et al. (12) showed that the nonspecific glycosidases
purified from rat cecal microorganisms were able to liberate
glucose, galactose, arabinose, rhamnose, and glucuronic acid
from soyasaponins during incubation. Thus, mammalian gut
microbial enzymes had the ability to hydrolyze various soyasa-
ponin glycosidic bonds. Human intestinal bacteria, especially
Lactobacilli, Bacteroides, and Bifidobacteria species, possess
glycosidase and â-glucuronidase activities (15, 24). R-L-
Rhamnosidase is reportedly produced by some strains of human
intestinal Bacteroides (20, 25). These bacterial enzymes might
play a major role in liberating the aglycones from sugar-
conjugated soyasaponins in the human gut. Food residue remains
in the large intestine 24 h or longer. Microbes in the large bowel
would have sufficient time to interact with and hydrolyze
soyasaponins. Further study will be needed to identify the
bacterial species in the human intestinal tract that metabolize
soyasaponins.
In our in vitro incubation study, soyasaponin III and soyasa-
pogenol B were identified as the major microbial metabolites
of soyasaponin I, implying their possible existence in the human
gut. A few studies investigated the biological activity of these
soyasaponin metabolites. The variety and number of sugars
attached to soyasapogenols have profound impact on their
activity. Ikeda et al. (26) found that soyasaponins with a
disaccharide group such as soyasaponin III and IV had more
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potent hepatoprotective activity against immunologically in-
duced damage than those with a trisaccharide group such as
soyasaponin I and II and soyasapogenol B in the primary
cultured rat hepatocytes. Soyasapogenol B had more potent
activity than its various glycosides in suppressing 2-acetoxy-
acetylaminofluorene-induced genotoxicity in Chinese hamster
ovary cells (27). Soyasapogenol B showed antiproliferative
activity in human breast cancer cell lines MCF-7 and MDA-
MB-231 in vitro (28). Therefore, the bioavailability and potential
biological activities of these soyasaponin metabolites deserve
further characterization due to their probable presence in the
human lower intestinal tract.
The metabolism of soyasaponin I showed a biphasic pattern
during 48 h of incubation in the in vitro culture model (Figure
Figure 2. Ion chromatograms of soyasaponin I (A), soyasaponin III (B), and soyasapogenol B (D) standards with a positive mode ApCI-MS detection.
The chromatograms of 12 and 48 h fecal incubation extracts from one subject are shown in panels C and E, respectively.
2692 J. Agric. Food Chem., Vol. 52, No. 9, 2004 Hu et al.
5). No significant degradation of soyasaponin I was observed
during the first 4 h. Soyasaponin I content significantly
decreased from 4 to 48 h in the culture system. The absence of
soyasaponin I metabolism at the early stage of incubation may
be because the microorganisms need time to adapt to the culture
environment before they produce sufficient enzymes to me-
tabolize soyasaponins. Soyasaponin III was produced in fecal
incubations for 13 out of 15 subjects. Soyasapogenol B was
detected in fecal incubations for all of the subjects.
The rate loss of the natural logarithm of soyasaponin I
concentration over the incubation time gave a linear relationship
for all subjects (Figure 6), indicating that disappearance of
soyasaponin I followed apparent first-order kinetics. The disap-
pearance of soyasaponin I in the presence of human gut
microorganisms varied among subjects. The average disappear-
ance rate loss constant was 0.15 ( 0.10 h-1 and half-lives t1/2
of soyasaponin I in the culture ranged from 2.2 to 19.1 h among
the subjects. Two distinct soyasaponin I disappearance pheno-
types were observed among the subjects according to rate
constants (Figure 6). The rate constants and half-lives of the
two phenotypic groups were significantly different (P < 0.05):
rapid soyasaponin degraders (n ) 7) having a rate constant of
k ) 0.24 ( 0.04 h-1and t1/2 ) 3.16 ( 0.62 h; slow soyasaponin
degraders (n ) 8) having a k ) 0.07 ( 0.02 h-1 and t1/2 )
11.15 ( 4.34 h. The data demonstrate that the ability of gut
microorganisms to metabolize soyasaponins varied among our
Figure 3. Positive mode ApCI mass spectra of soyasaponin I (A), soyasaponin III (B), and soyasapogenol B (C).
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subjects and that two soyasaponin metabolic phenotypes were
present. If the ability to metabolize soyasaponins in the gut was
a stable characteristic in humans, enhanced bioavailability and
bioactivity of soyasaponins might be expected among the
subjects exhibiting relatively longer soyasaponin half-life in the
intestinal tract, whereas the subjects metabolizing soyasaponins
rapidly would more likely experience effects of the metabolites.
The two groups of subjects having different soyasaponin I
disappearance phenotypes are likely to have different gut
microbial enzyme activities. Gut microbial population and fecal
enzyme activities may be influenced by genetic background of
individuals, dietary factors, physical activity, and gut motility
(29). We examined the relationship of BMI, fecal moisture,
GGT, and soy consumption frequency to the ability of the
subjects’ feces to metabolize soyasaponins. The subjects’ BMI
ranged from 18.1 to 30.4 kg/m2. Fecal moisture ranged from
47.2 to 78.3%. GGTs ranged from 38 to 168 h. There were no
significant differences in BMI and fecal moisture between the
two soyasaponin metabolic phenotypes (Table 2). The slow
soyasaponin degraders seemed to have longer GGTs than rapid
soyasaponin degraders although this was not statistically
significant at R ) 0.05. Zheng et al. (17) reported that GGT
differed between high and low isoflavone degradation pheno-
types among subjects who were recent Chinese immigrants to
the U.S., and rapid GGT coupled with low fecal isoflavone
degradation produced greater isoflavone bioavailability. Ac-
cording to their self-reported soy consumption, five subjects
usually consumed soy foods more than once per week, five
subjects consumed soy foods more than once a month but less
than once per week, and five consumed soy less than once a
month or not at all. Soy consumption frequencies did not differ
according to soyasaponin metabolic rate. However, self-reported
soy consumption may not have been accurate. Many food
products contain soy ingredients that the subjects may not have
realized and did not report. A detailed dietary assessment might
be needed in the future in order to elucidate the role of dietary
factors in soyasaponin metabolism. Overall, the absence of a
significant difference in these factors between the two soyasa-
ponin degradation phenotypes might also be due to the small
sample size in our study, limiting statistical power. To further
examine the influence of genetic and dietary factors as well as
GGT on soyasaponin metabolism, a larger population group
must be studied.
Our present study may provide insight into the role of gut
microorganisms in soyasaponin bioavailability and biological
potency. The potential of soyasaponins to lower blood choles-
terol has been proposed. Soyasaponins could form insoluble
complexes with cholesterol and interfere with reabsorption of
bile acids and cholesterol by forming mixed micelles (3, 30).
Soyasaponins were anticarcinogenic in an animal model of colon
cancer (7). The colon cancer inhibiting activity of soyasaponins
may be partly due to antimutagenic, cytotoxic, and/or dif-
Table 1. TLC, HPLC, and Mass Spectral Data of Soyasaponin I and III and Soyasapogenol B
molecular
weighta TLC Rf HPLC retention time ApCI-mass spectra (positive mode)
soyasaponin I
C48H78O18
943.1 0.60 (butanol−
ethanol−ammonia)
25.9 min by program 1 943.8 [M + H]+, 797.4 [M-rhm + H]+, 599.4
[M-glc-gal-2H2O + H]+, 441.3 [aglycone − OH]+,
423.4 [aglycone − OH − H2O]+, 405
[aglycone − OH − 2H2O]+ on ApCI
soyasaponin III
C42H68O14
797.0 0.63 (butanol−
ethanol−ammonia)
29.9 min by program 1 797.3 [M + H]+, 599.4 [M-rhm-gal-2H2O + H]+,
441.3 [aglycone − OH]+, 423.3 [aglycone − OH − H2O]+,
405.3 [aglycone − OH − 2H2O]+ on ApCI
soyasapogenol B
C30H50O3
458.6 0.43 (hexane:
ethyl acetate)
27.2 min by program 2 441.3 [aglycone − OH]+, 423.3 [aglycone − OH − H2O]+,
405.4 [aglycone − OH − 2H2O]+ on ApCI
a The molecular weight is a calculated value based on the molecular formula.
Figure 4. Comparison of in vitro metabolism of soyasaponin I in fecal
fermentation system among different experimental treatments. Each bar
represents the value of the mean ± SD of three replicates.
Figure 5. In vitro metabolism of soyasaponin I in fecal fermentation system
measured by HPLC. Disappearance of soyasaponin I and appearance of
its metabolites I and II were monitored at UV 205 nm. Each point
represents the value of the mean ± SD of three replicates.
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ferentiation-inducing effects observed in cancer cell lines (8,27,
31). Soyasaponins could reduce the formation of secondary bile
acids in the gut, which probably contributes to colon cancer
inhibition by soyasaponins because secondary bile acids are
known colon cancer promoters (32). Thus, slow soyasaponin
degraders would be able to retain original soyasaponins longer
in the gut to interact with cholesterol and bile acids, therefore
having greater cholesterol lowering and colon cancer inhibiting
effects from ingested soyasaponins. On the other hand, rapid
soyasaponin degraders might have higher concentrations of
soyasapogenols in the gut from soy ingestion, thus experiencing
a greater bioavailability and impact from these soyasaponin
aglycones.
The data from this study indicate metabolism of soyasaponin
I by human gut microbial enzymes to soyasapogenol B and
soyasaponins with fewer or no sugars attached to the aglycone.
It is reasonable to infer that other forms of soyasaponins may
be metabolized in the gut in the same manner. Two distinguish-
able soyasaponin metabolic phenotypes, slow and rapid soyasa-
ponin degraders, were observed among human subjects in our
study, implying that different people might experience different
biological effects from soyasaponin ingestion. It is important
to further characterize the factors that influence interindividual
variation in the ability to metabolize soyasaponins in the gut.
In addition, studies of the biological activities of soyasaponins
and their gut metabolites are needed to evaluate the health
promoting role of dietary soyasaponins.
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